


Curriculum Vitae

Name	Ken Kato	
Current Position & Affiliation	Chief, Department of Head and Neck Medical Oncology, National Cancer Center Hospital	
Country	Japan	

Educational Background

1989	University of Occupational and Environmental Health, School of Medicine, Kitakyushu, Japan
1995	M.D. Graduated from University
2001	Ph.D. Kyushu University, Graduate School of Medicine, Fukuoka, Japan

Professional Experience

2004-2006	Chief Resident, National Cancer Center Hospital, Tokyo
2006-2012	Medical staff, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo
2013-Present	Chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office
2020-Present	Chief, Department of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo

Professional Organizations

Chief, Department of Head and Neck Medical Oncology
Head Physician, Department of Gastrointestinal Medical Oncology
Chief, Biobank Translational Research Support Section, Clinical Research
Coordinating Section, Clinical Research Support Office
National Cancer Center Hospital, Tokyo, Japan

Main Scientific Publications

- 2020 Kojima T, Kato K, et al. Randomized Phase 3 KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer *J Clin Oncol*. 2020 Dec 10;38(35):4138-4148
- 2020 Nakamura Y, Kato K, et al. Clinical Utility of Circulating Tumor DNA Sequencing in Advanced Gastrointestinal Cancer: SCRUM-Japan GI-SCREEN and GOZILA Studies *Nat Med* 2020 Dec;26(12):1859-1864.
- 2019 Kato K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Sep 27.: S1470-2045(19)30626-6.
- 2019 Kato K, et al. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2). *Gastric Cancer*. 2019 Mar;22(2):344-354.